

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-69. (Canceled)

70. (Currently amended) A method for making a cell that produces a therapeutically hypermutated immunogen comprising the steps of:

introducing into a cell that expresses a gene encoding a preselected immunogen *in vitro* a polynucleotide comprising a dominant negative allele of a mismatch repair gene, wherein said dominant negative allele is a truncation mutant of a PMS2,

selecting cells that comprise a mutation in said gene encoding said preselected immunogen; and

expressing a polynucleotide sequence of said mutated gene encoding said preselected immunogen in a genetically stable cell.

71. (Canceled)

72. (Currently amended) The method of claim 70 ~~or 71~~ wherein said introduction of said polynucleotide is in the presence of at least one DNA mutagen.

73. (Currently amended) The method of claim 70 ~~or 71~~ wherein the PMS2 mismatch repair gene is human PMS2.

74. (Previously Presented) The method of claim 73 wherein the allele comprises a truncation mutation at codon 134.

75. (Previously Presented) The method of claim 74 wherein the truncation mutation is a thymidine at nucleotide 424 of wild-type PMS2.

76. (Currently amended) The method of claim 70 ~~or 71~~ wherein said step of selecting cells is based on a determination that the polynucleotide encoding said preselected

**DOCKET NO.:** MOR-0277  
**Application No.:** 10/813,502  
**Office Action Dated:** November 17, 2005

**PATENT**

immunogen comprises a mutation as compared to the polynucleotide of a parental cell prior to introduction of said dominant negative allele of a *PMS2* mismatch repair gene

77. (Currently amended) A homogeneous culture of cells produced by the method of claim 70 or 71.